Research Progress of Non-coding RNAs in Tumor Drug Resistance
DOI:
https://doi.org/10.54097/7e1y0g78Keywords:
Non-coding RNA, Tumor drug resistance, Biomarker, Therapeutic application.Abstract
In recent years, research of non-coding RNAs(ncRNAs)’ role in tumor drug resistance has made significant progress. Studies have revealed that various types of ncRNAs contribute to the emergence of tumor drug resistance through diverse mechanisms. NcRNAs are also showing promise as biomarkers for predicting drug resistance in various tumors. Furthermore, therapeutic strategies based on ncRNAs offer new opportunities to overcome drug resistance, although their clinical translation faces considerable challenges. This review is concentrated on the classification of ncRNAs, their roles in tumor drug resistance, their value as biomarkers, proposed therapeutic strategies, and the challenges and prospects for clinical translation.
Downloads
References
[1] Lopez-Otin, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023). Meta-hallmarks of aging and cancer [Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review]. Cell Metabolism, 35 (1), 12 - 35. http://doi.org/10.1016/j.cmet.2022.11.001.
[2] Anczukow, O., Airhart, S., Chuang, J. H., Coussens, L. M., Kuchel, G. A., Korstanje, R., Li, S., Lucido, A. L., McAllister, S. S., Politi, K., Polyak, K., Ratliff, T., Ren, G., Trowbridge, J. J., Ucar, D., & Palucka, K. (2023). Challenges and opportunities for modeling aging and cancer [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.]. Cancer Cell, 41 (4), 641 - 645. http://doi.org/10.1016/j.ccell.2023.03.006.
[3] Taghvimi, S., Abbaszadeh, S., Banan, F. B., Fard, E. S., Jamali, Z., Najafabadi, M. A., Savardashtaki, A., & Movahedpour, A. (2022). LncRNAs Roles in Chemoresistance of Cancer Cells [Journal Article; Review]. Current Molecular Medicine, 22 (8), 691 - 702. http://doi.org/10.2174/1566524021666211027090515.
[4] Slack, F. J. (2006). Regulatory RNAs and the demise of 'junk' DNA [Congress]. Genome Biology, 7(9), 328. http://doi.org/10.1186/gb - 2006 - 7 - 9 - 328.
[5] Mattick, J. S., Amaral, P. P., Carninci, P., Carpenter, S., Chang, H. Y., Chen, L. L., Chen, R., Dean, C., Dinger, M. E., Fitzgerald, K. A., Gingeras, T. R., Guttman, M., Hirose, T., Huarte, M., Johnson, R., Kanduri, C., Kapranov, P., Lawrence, J. B., Lee, J. T., Mendell, J. T., Mercer, T. R., Moore, K. J., Nakagawa, S., Rinn, J. L., Spector, D. L., Ulitsky, I., Wan, Y., Wilusz, J. E., & Wu, M. (2023). Long non-coding RNAs: definitions, functions, challenges and recommendations [Journal Article; Research Support, N.I.H., Extramural; Review]. Nature Reviews Molecular Cell Biology, 24 (6), 430 - 447. http://doi.org/10.1038/s41580 - 022 - 00566 - 8.
[6] Shen, L., Wang, Q., Liu, R., Chen, Z., Zhang, X., Zhou, P., & Wang, Z. (2018). LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA [Journal Article; Research Support, Non-U.S. Gov't]. Nucleic Acids Research, 46 (2), 717 - 729. http://doi.org/10.1093/nar/gkx1224.
[7] Ma, B., Wang, S., Wu, W., Shan, P., Chen, Y., Meng, J., Xing, L., Yun, J., Hao, L., Wang, X., Li, S., & Guo, Y. (2023). Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomedicine & Pharmacotherapy, 162, 114672. http://doi.org/10.1016/j.biopha.2023.114672.
[8] Liu, H. T., Gao, Z. X., Li, F., Guo, X. Y., Li, C. L., Zhang, H., Zhao, R. N., Liu, Y., Shi, D. B., Zhu, W. J., & Gao, P. (2024). LncRNA LY6E-DT and its encoded metastatic-related protein play oncogenic roles via different pathways and promote breast cancer progression [Journal Article; Research Support, Non-U.S. Gov't]. Cell Death and Differentiation, 31 (2), 188 - 202. http://doi.org/10.1038/s41418 - 023 - 01247 - 5.
[9] Xu, H., Zhang, H., Wang, H., Zhao, Q., & Lu, J. (2022). Effects of IncRNA GAS6 - AS1 on the proliferation and radiotherapy sensitivity of glioma T98G cells by targeting miR - 324 - 3p to activate Wnt/β - catenin pathway. Hebei Medical Journal, 44 (19), 2885 - 2890.
[10] Zhang, N., Wang, X., Li, Y., Lu, Y., Sheng, C., Sun, Y., Ma, N., & Jiao, Y. (2025). Mechanisms and therapeutic implications of gene expression regulation by circRNA-protein interactions in cancer [Journal Article; Review]. Communications Biology, 8 (1), 77. http://doi.org/10.1038/s42003-024-07383-z.
[11] Zhang, Y., Song, X., Feng, Y., Qian, Y., Chen, B., Zhang, T., Wang, H., Chen, Y., Yu, X., Ding, H., Li, R., Ge, P., Xu, L., Dong, G., & Jiang, F. (2025). The circRNA cEMSY Induces Immunogenic Cell Death and Boosts Immunotherapy Efficacy in Lung Adenocarcinoma [Journal Article]. Cancer Research, 85(3), 497-514. http://doi.org/10.1158/0008-5472.CAN-24-1484.
[12] Zhou, H., Yao, Y., Li, Y., Guo, N., Zhang, H., Wang, Z., Chen, Y., & Dai, G. (2022). Identification of Small Nucleolar RNA SNORD60 as a Potential Biomarker and Its Clinical Significance in Lung Adenocarcinoma [Journal Article]. Biomed Research International, 2022, 5501171. http://doi.org/10.1155/2022/5501171.
[13] Cui, C., Liu, Y., Gerloff, D., Rohde, C., Pauli, C., Kohn, M., Misiak, D., Oellerich, T., Schwartz, S., Schmidt, L. H., Wiewrodt, R., Marra, A., Hillejan, L., Bartel, F., Wickenhauser, C., Huttelmaier, S., Gollner, S., Zhou, F., Edemir, B., & Muller-Tidow, C. (2021). NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration [Journal Article; Research Support, Non-U.S. Gov't]. Oncogene, 40 (5), 909 - 921. http://doi.org/10.1038/s41388 - 020 - 01570 - y.
[14] Zou, W., Zhang, Y., Bai, G., Zhuang, J., Wei, L., Wang, Z., Sun, M., & Wang, J. (2022). siRNA-induced CD44 knockdown suppresses the proliferation and invasion of colorectal cancer stem cells through inhibiting epithelial-mesenchymal transition [Journal Article]. Journal of Cellular and Molecular Medicine, 26 (7), 1969 - 1978. http://doi.org/10.1111/jcmm.17221.
[15] Yao, J., Wang, Y. W., Fang, B. B., Zhang, S. J., & Cheng, B. L. (2016). piR-651 and its function in 95-D lung cancer cells [Journal Article]. Biomedical Reports, 4 (5), 546 - 550. http://doi.org/10.3892/br.2016.628.
[16] Zhou, H. Z., Li, M. W., & Xu, H. M. (2018). Recent Progress in Molecular Mechanism of Tumor Drug Resistance Regulated by Long Non-Coding RNA. Pharm Biotechnol, 25 (01), 75 - 80. http://doi.org/10.19526/j.cnki.1005 - 8915.20180116.
[17] Wang, L., & Xu, X. M. (2025). Mechanism of microRNA in drug resistance in hepatocellular carcinoma. Medical Journal of Wuhan University, 46(05), 683-688. http://doi.org/10.14188/j.1671 - 8852.2023.0171.
[18] LIU, Q., & XIAO, G. S. (2025). Study of miR-483-3p increasing sensitivity of pancreatic cancer to gemcitabine and molecular mechanism. Journal of Dalian University of Technology, 65 (01), 30 - 37.
[19] SHANG, H. Y., YAO, M. M., LU, Y. T., WANG, D. X., ZHAO, Q., & LIU, T. J. (2024). Research progress of long non - coding RNA CASC2 in tumor chemotherapy resistance. Oncology Journal Practical, 38 (01), 67 - 70.
[20] Xie, S., Li, Y., Mai, L., Gao, X., Huang, G., Sun, W., Qiao, L., Li, B., Wang, Y., & Lin, Z. (2024). A tumor-promotional molecular axis CircMAPKBP1/miR-17-3p/TGFbeta2 activates autophagy pathway to drive tongue squamous cell carcinoma cisplatin chemoresistance [Journal Article]. Cancer Letters, 604, 217230. http://doi.org/10.1016/j.canlet.2024.217230.
[21] Wang, H., Gu, Y., Guo, M., Zhan, M., He, M., Zhang, Y., Yang, L., & Liu, Y. (2025). Small nucleolar RNA host gene 1 (SNHG1) facilitates gemcitabine chemosensitivity in gallbladder cancer by regulating the miR-23b-3p/phosphatase and tensin homolog (PTEN) pathway [Journal Article]. Chinese Medical Journal http://doi.org/10.1097/CM9.0000000000003482.
[22] Pan, Z., Zheng, J., Zhang, J., Lin, J., Lai, J., Lyu, Z., Feng, H., Wang, J., Wu, D., & Li, Y. (2022). A Novel Protein Encoded by Exosomal CircATG4B Induces Oxaliplatin Resistance in Colorectal Cancer by Promoting Autophagy [Journal Article; Research Support, Non-U.S. Gov't]. Advanced Science, 9 (35), e2204513. http://doi.org/10.1002/advs.202204513.
[23] Rong, Z., Xu, J., Yang, J., Wang, W., Tang, R., Zhang, Z., Tan, Z., Meng, Q., Hua, J., Liu, J., Zhang, B., Liang, C., Yu, X., & Shi, S. (2024). CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression [Journal Article]. Cancer Research, 84 (24), 4246 - 4263. http://doi.org/10.1158/0008-5472.CAN - 23 - 3596.
[24] Huang, K., Han, Y., Chen, Y., Shen, H., Zeng, S., & Cai, C. (2025). Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy [Journal Article; Review]. Molecular Cancer, 24 (1), 7. http://doi.org/10.1186/s12943 - 024 - 02205 - 6.
[25] Chattopadhyay, T., Biswal, P., Biswal, S., & Mallick, B. (2025). A piRNA chemosensitizes doxorubicin in tongue squamous cell carcinoma by targeting FDFT1 and inhibiting the EIF3H/HIF1alpha/CYPOR axis [Journal Article]. Archives of Biochemistry and Biophysics, 770, 110455. http://doi.org/10.1016/j.abb.2025.110455.
[26] Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025). Resistance mechanisms to immune checkpoint inhibitors: updated insights [Journal Article; Review]. Molecular Cancer, 24(1), 20. http://doi.org/10.1186/s12943 - 024 - 02212 - 7.
[27] Zhan, Y., Tian, F., Fan, W., Li, X., Wang, X., Zhang, H., Hong, X., Wang, X., Cai, L., Song, Y., & Xing, Y. (2025). Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma [Journal Article]. Advanced Science, 12 (6), e2414100. http://doi.org/10.1002/advs. 202414100.
[28] Saxena, T., Quan, A., Chan, E., Kozlova, N., Matai, L., Lee, J. D., Rupaimoole, R., Beca, F., Muranen, T., & Slack, F. J. (2025). EGFR-induced lncRNA TRIDENT promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair [Journal Article]. Proceedings of the National Academy of Sciences of the United States of America, 122 (10), e1879578174. http://doi.org/10.1073/pnas.2415389122.
[29] Li, Y., Wu, A., Chen, L., Cai, A., Hu, Y., Zhou, Z., Qi, Q., Wu, Y., Xia, D., Dong, P., Ju, S., & Wang, F. (2022). Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin. Journal of Experimental & Clinical Cancer Research, 41 (1), 267. http://doi.org/10.1186/s13046 - 022 - 02482 - 3.
[30] Bergamini, C., Leoni, I., Rizzardi, N., Melli, M., Galvani, G., Coada, C. A., Giovannini, C., Monti, E., Liparulo, I., Valenti, F., Ferracin, M., Ravaioli, M., Cescon, M., Vasuri, F., Piscaglia, F., Negrini, M., Stefanelli, C., Fato, R., Gramantieri, L., & Fornari, F. (2023). MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma [Journal Article]. Journal of Experimental & Clinical Cancer Research, 42(1), 145. http://doi.org/10.1186/s13046 - 023 - 02718 - w.
[31] Chen, B., Dragomir, M. P., Yang, C., Li, Q., Horst, D., & Calin, G. A. (2022). Targeting non-coding RNAs to overcome cancer therapy resistance [Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review]. Signal Transduction and Targeted Therapy, 7 (1), 121. http://doi.org/10.1038/s41392 - 022 - 00975 - 3.
[32] Wang, M., & Yuan, H. (2025). Study on the effect of antisense oligonucleotide combined with cetuximab in the treatment of oral squamous cell carcinoma. Proceedings of 2025 CACA Conference on Tumor Markers, Conference on Industrial Innovation of Tumor Markers, Conference for Young Scientists of Tumor Markers & Conference on Integrative Oncology.
[33] DONG, J., SHANG, S., & XIE, F. (2023). Effect of RNA interference with ITGA5 expression on cervical cancer cell growth and invasion. Fudan University Journal of Medical Sciences, 50 (03), 330 - 336.
[34] Wang, T., Liu, Y., Wu, X., Wang, X., Shi, S., Song, X., Ma, Y., Zhang, Z., Gao, J., Sun, R., & Song, G. (2025). Multi-omics reveals miR-181a-5p regulates PPAR-driven lipid metabolism in Oral squamous cell carcinoma: Insights from CRISPR/Cas9 knockout models [Journal Article]. Journal of Proteomics, 319, 105480. http://doi.org/10.1016/j.jprot.2025.105480.
[35] YAN, Q., BIAN, S. S., & SHU, M. F. (2024). Double - stranded RNA inhibits the growth and migration of malignant gliomas through the activation of the PKR/eIF2a pathway. Fudan University Journal of Medical Sciences, 51 (03), 295 - 305.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic Journal of Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
